title: Food and Drug Administration recommends against the continued use of propoxyphene.
abstract: Following receipt of a Citizens' petition, the Food and Drug Administration (FDA) convened an advisory committee to address the safety of propoxyphene. This led to a comprehensive review that culminated in a November 19, 2910, press release in which the FDA recommended against continued use of the drug. The FDA release contains a data summary (background), a safety announcement, additional Information for Patients, additional information for health care professionals, and references. All dosage forms of the drug have now been withdrawn from the United States market.
authors.lastname: Food And Drug Administration Public Health Service U S Department Of Health And Human Services
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects*; D011431:Dextropropoxyphene / Q000009:adverse effects*; D006801:Humans; D056737:Safety-Based Drug Withdrawals / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D011431:Dextropropoxyphene